Free Webinars offered by PELOBiotech.

Islet Isolation Success of Chronic Pancreatitis Pancreas & Brain-Dead Donor Pancreas Intended for Auto & Allo-Transplantation

presented by Balamurugan N. Appakalai, PhD, Nationwide Children’s Hospital and hosted by VitaCyte, Indianapolis, USA

Date&Time: April 11, 5 PM (CET)|11 AM (EST)

Recovery of human islets from pancreata recovered from brain-dead donors and chronic pancreatitis patients for subsequent transplantation requires consideration of different factors. Isolating islets from pancreata from donors with a high BMI has a higher probability of success than isolating islets from donors with a low BMI. The choice of neutral protease and control of the ratio of collagenase/protease activities is critical since it affects the percentages of free and embedded islets.

EMERGE 17 | Streamlined proteome-wide identification of drug targets indicates organ-specific engagement

presented by Tanveer Batth, Novo Nordisk, Center for Protein Research, Danmark and ReSyn Biosciences, South Africa

Proteins are the primary targets of almost all small-molecule drugs. Even drugs designed with high specificity may interact with multiple proteins that are not initially targeted. Discovering these potential interactions is crucial for the development and repurposing of drugs. We report the development of a label-free quantitative proteomics approach that enables proteome-wide screening of small organic molecules in a scalable, reproducible, and rapid manner by streamlining the proteome integral solubility alteration (PISA) assay. Tanveer is a researcher at the NNF CPR in Denmark.

EMERGE Episode 16 | The potential of plasma HLA peptides beyond neoepitopes

presented by Maria Wahle, PhD student, Max-Planck-Institute of Biochemistry, Munich and and ReSyn Biosciences, South Africa

Soluble HLA (sHLA) peptides are thought to have great potential as biomarkers for different diseases such as cancer. However, efficient enrichment of sHLA peptides from body fluids like plasma has been a bottleneck, requiring 3-5 ml per patient. Maria presents IMBAS-MS, an automated magnetic bead-based workflow for the efficient enrichment of HLA protein-peptide complexes. The core of IMBAS-MS is the combination of biotinylated antibodies immobilized on streptavidin magnetic beads allowing for an automated one-pot enrichment from only 200 µl of plasma.

PELOAcademy | From our Lab: Exploring the Advantages of Animal Component-Free Media in Cell Culture

presented by Anna Lena Schuhmacher, University of Applied Sciences, Weihenstephan & Dr. Lothar Steeb, CSO&CEO PELOBiotech

We compare traditional animal component-based media with the emerging animal component-free alternatives. This webinar will provide an in-depth analysis of the benefits and potential challenges associated with animal component-free media, including considerations such as cell growth, viability, functionality, and downstream applications.

PELOAcademy | Stem Cell Culture: Differences, Properties, Prospects, Applications

presented by Prof. Dr. Gerhard Gstraunthaler, Institut für Physiologie der Medizinischen Universität Innsbruck, emer

Stem cells are unique cell populations that retain the capability of either self-renewal in nearly infinite cell divisions or to differentiate into somatic cell types (asymmetric cell division). In this webinar the challenges in stem cell culture techniques, the types and characteristics of stem cells, and their applications and future perspectives will be discussed.

PELOAcademy: Clinical Potential of MSC-EVs and Translational Challenges

Prof. Dr. rer. nat. Bernd Giebel, Universitätsklinikum Essen (AöR), Institut für Transfusionsmedizin

Human mesenchymal stromal cells (MSCs) are a therapeutically relevant, heterogenous cell entity with immunomodulatory and pro-regenerative potentials. Apparently, MSCs mediate a huge proportion of their therapeutic effects via extracellular vesicles (EVs). Connected to several advantages in using cell-free products for the therapeutic setting, MSC-EVs emerged as promising novel therapeutic agent for various diseases, including graft-versus-host disease (GvHD), ischemic stroke, COVID-19, and sepsis. Learn more about a lentiviral, hTERT-based immortalization strategy, EVs and immortalized MSCs (ciMSCs).

Considerations & Testing: Using Primary Hepatocytes in 2D and 3D Cell Culture

presented by Dr. Rafal P. Witek, a KOL in the hepatocyte sector, hosted by our partner AnaBios

Review selection criteria and sources of variabilities including donor variabilities, process variabilities, and functional stability that impact the performance of cryopreserved primary hepatocytes when used in In Vitro cell culture. Different criteria for 2D and 3D use will be covered to enable participants to understand how to select the best-performing primary hepatocyte lots for their studies. We cover also best practices when handling primary hepatocytes during storage, after thawing, during plating, and during 3D aggregation to overcome challenges related to data reproducibility and variability.

PELOAcademy | Brain organoids: A versatile 3D tool to study human neurological development and disease

presented by Dr. Insa S. Schroeder, GSI Helmholtzzentrum für Schwerionenforschung Darmstadt, Germany

Brain organoids, derived from human pluripotent stem cells, revolutionize neuroscience.  The lecture introduces organoids and covers generation techniques, region-specific specialization, and their role in modeling neurological diseases. Explore their potential for disease research, drug development, ethical considerations, and their ability to mimic human brain development.

MSCs and Exosomes Therapeutics: Lessons Learned and a Promising Future

presented by Kevin Hicok, KCH-Cell-Tx Consulting
and hosted by Rob McCarthy, VitaCyte

Clinical research explored the use of mesenchymal stem cells (MSCs) to improve islet engraftment or suppress the immune response to allo-islets. The webinar will address the questions you may have about MSCs such as: what tissues contain MSCs and how are they isolated? How do they work? What is the status of MSCs as the primary or supplementary cell therapy?

EMERGE Episode 15 | Analysis of Quantitative MS-based Proteomics Experiments using MSstats and MSstatsTMT”

presented by Devon Kohler, Khoury College of Computer Sciences at Northeastern University, USA and ReSyn Biosciences, South Africa

In this webinar we will review the core workflow and methods behind MSstats and its extensions, highlighting critical choices that need to be made in each step of the analysis. We will review how different analysis choices affect the final protein-level conclusions made on the experiment and discuss how to avoid potential analysis pitfalls.

Certificates of Analysis for Tissue Dissociation Enzymes: Practical Utility

presented Robert McCarthy, VitaCyte, USA

Enzyme suppliers provide Certificates of Analysis (CoAs) for each lot of product purchased by the customer. The primary enzyme manufacturer or the companies re-selling the manufacturer’s product use these CoAs to report the results of quality testing and acceptance criteria used to release the product for sale. The specification limits set internally by the manufacturer are guided by customer feedback or by internal decisions to ensure the majority of lots pass specifications.

PELOAcademy: Why the Best Suitable Media is Important for Exosome Production

presented by Hyungtaek Jeon, Xcell Therapeutics, Institute of Life Science, Korea

Mesenchymal stem cells (MSCs) are commonly used as a source of regenerative medicine due to their strong immunosuppressive and regenerative effects. The paracrine effect is one of the key mechanisms of MSC. Recently, it has been shown that extracellular vesicles (EVs), which include exosomes and microvesicles, orchestrate the principle mechanisms of action of MSCs after infusion.

Join: the discussion what is the ideal culture environment for the production of exosomes.

Expect: MSC-derived exosome productivity is compared using several media including CDM. Wound healing assay and angiogenesis assay were conducted to evaluate the characteristics of the produced exosomes.

PELOAcademy | Biomimicry at Nanoscale Level: a Step Forward Towards Organotypic Cell Studies

presented by Prof. Matteo Santin, Director of the Centre for Regenerative Medicine and Devices, School of Applied Sciences, University of Brighton, UK

The lecture will show the ability of a novel class of biomimetic biomaterials substrates, PhenoDrive (Tissue Click Ltd, UK), to support the formation of 3D organ- and tissue-like structures while operating in traditional 2D cell cultures. The potential of these tissue engineering constructs in testing novel nanomedicines will be explored.

EMERGE Episode 14 |

Using an Orbitrap for Phosphoproteomics: Exploring the Effect of Some Parameters on Quantity and Quality

presented by Seamus Morrone, Institute for Systems Biology Seatle, USA and ReSyn Biosciences, South Africa

Phosphoproteomics is a biologically important and dynamic field. Data-dependent mass spectrometry (DDA-MS) is the current gold standard for phosphoproteomics and high-throughput sample preparation is quickly becoming the norm, allowing access to instrumentation and data.

EMERGE Episode 13 |

Development and optimization of a HTS proteomics workflow for biomarker discovery in clinical cohorts

presented by Sergio Mosquim Junior, University of Lund, Sweden  and ReSyn Biosciences, South Africa  

Breast cancer is the most diagnosed cancer in the world. We establish a new semi-automated bead-based workflow for high-throughput processing of clinical samples, and further evaluate different acquisition methods.

EMERGE Episode 12  |

RNA-Protein interactions in Space and Time

presented by Eneko Verdejo, University of Cambridge, UK and ReSyn Biosciences, South Africa  

The webinar will focus on two multi-omics methodologies that probe the crosstalk between the RNA and the protein worlds, with a specific focus on characterizing RNA-protein interactions and RNA and protein subcellular localisation.

EMERGE Episode 11  | 

Protein aggregation capture sample preparation provides a platform for MS-based secretomics in the study of metabolism

presented by Daniel Cervone, Novo Nordisk Foundation Center for Basic Metabolic Research, Denmark, and ReSyn Biosciences, South Africa

Sample preparation for ‘bottom-up’ proteomics is a major determinant for efficient sample clean-up and digestion, strongly influencing downstream peptide identifications and analyses. The team identified novel proteins potentially involved in inter-organ crosstalk and metabolism.